PSPaul Sargos

Paul Sargos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul Sargos has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Amélie Aboudaram

    Department of Radiation Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse—Oncopole, 31000 Toulouse, France

    1 shared publication
  • Christine Chevreau

    IGR, Villejuif, France; C. Leon Berard, Lyon, France; Inst Claudius Regaud, Toulouse, France; Hop Tenon, Paris, France; Centre Alexis Vautrin, Nancy, France; C. Eugene Marquis, Rennes, France; Inst Bergonie, Bordeaux, France; Sanofi-Synthelabo, France, France

    1 shared publication
  • Damien Pouessel

    Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse—Oncopole, 31059 Toulouse, France

    1 shared publication
  • Elizabeth Cohen-Jonathan Moyal

    INSERM Cancer Research Center INSERM Cancer Research Center INSERM Cancer Research Center IRT Saint Exupéry of Toulouse Toulouse IRT Saint Exupéry of Toulouse Toulouse Toulouse Toulouse

    1 shared publication
  • Gilles Créhange

    Department of Radiotherapy, Institut Curie, 75005 Paris, France

    1 shared publication
  • Jonathan Khalifa

    Department of Radiation Oncology, Oncopole Claudius-Regaud, Toulouse, France; Inserm, U1037, Centre de recherches en cancérologie de Toulouse, Toulouse, France

    1 shared publication

Latest Publications

  • Open Access

    Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis

    by Amélie Aboudaram, Léonor Chaltiel, Damien Pouessel, Pierre Graff-Cailleaud, Nicolas Benziane-Ouaritini, Paul Sargos, Ulrike Schick, Gilles Créhange, Elizabeth Cohen-Jonathan Moyal, Christine Chevreau, et al.

    Local consolidative radiotherapy in the treatment of metastatic malignancies has shown promising results in several types of tumors. The objective of this study was to assess consolidative radiotherapy to the bladder and to residual metastases in metastatic urothelial bladder cancer with no progression following first-line systemic therapy. Materials/methods: Patients who received first-line therapy for the treatment of metastatic urothelial bladder cancer (mUBC) and who were progression-free following treatment with no more than five residual metastases were retrospectively identified through the database of four Comprehensive Cancer Centers, between January 2005 and December 2018. Among them, patients who received subsequent definitive radiotherapy (of EQD2Gy > 45Gy) to the bladder and residual metastases were included in the consolidative group (irradiated (IR) group), and the other patients were included in the observation group (NIR group). Progression-free survival (PFS) and overall survival (OS) were determined from the start of the first-line chemotherapy using the Kaplan–Meier method. To prevent immortal time bias, a Cox model with time-dependent covariates and 6-month landmark analyses were performed to examine OS and PFS. Results: A total of 91 patients with at least stable disease following first-line therapy and with no more than five residual metastases were analyzed: 51 in the IR group and 40 in the NIR group. Metachronous metastatic disease was more frequent in the NIR group (19% vs. 5%, p = 0.02); the median number of metastases in the IR group vs. in the NIR group was 2 (1–9) vs. 3 (1–5) (p = 0.04) at metastatic presentation, and 1 (0–5) vs. 2 (0–5) (p = 0.18) after completion of chemotherapy (residual lesions), respectively. Two grade 3 toxicities (3.9%) and no grade 4 toxicity were reported in the IR group related to radiotherapy. With a median follow up of 85.9 months (95% IC (36.7; 101.6)), median OS and PFS were 21.7 months (95% IC (17.1; 29.7)) and 11.1 months (95% IC (9.9; 14.1)) for the whole cohort, respectively. In multivariable analysis, consolidative radiotherapy conferred a benefit in both PFS (HR = 0.49, p = 0.007) and OS (HR = 0.47, p = 0.015) in the whole population; in the landmark analysis at 6 months, radiotherapy was associated with improved OS (HR = 0.48, p = 0.026), with a trend for PFS (HR = 0.57, p = 0.082). Conclusion: Consolidative radiotherapy for mUBC patients who have not progressed after first-line therapy and with limited residual disease seems to confer both OS and PFS benefits. The role of consolidative radiotherapy in the context of avelumab maintenance should be addressed prospectively.